(2S,3S)-2,3-dihydroxybutanedioic acid; 5-bromo-N-[4,5-dihydro(4,4,5,5-2H4)-1H-imidazol-2-yl]quinoxalin-6-amine

• ChemBase ID: 162707
• Molecular Formular: C15H16BrN5O6
• Molecular Mass: 442.22144
• Monoisotopic Mass: 441.02839526
• SMILES: c12c(nccn1)ccc(c2Br)NC1=NCCN1.[C@@H]([C@H](O)C(=O)O)(O)C(=O)O
• Canonical SMILES: Brc1c(ccc2c1nccn2)NC1=NCCN1.OC(=O)[C@H]([C@@H](C(=O)O)O)O
• InChI: InChI=1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.0/s1
• InChIKey: QZHBYNSSDLTCRG-WUUYCOTASA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (2S,3S)-2,3-dihydroxybutanedioic acid; 5-bromo-N-[4,5-dihydro(4,4,5,5-^2H₄)-1H-imidazol-2-yl]quinoxalin-6-amine
• IUPAC Traditional name: 5-bromo-N-[(4,4,5,5-^2H₄)-1H-imidazol-2-yl]quinoxalin-6-amine; D-tartaric acid
• Synonyms: 5-Bromo-N-(4,5-dihydro-1H-imidazol-d4-2-yl)-6-quinoxalinamine D-Tartrate; 5-Bromo-6-(2-imidazolin-d4-2-ylamino)quinoxaline D-Tartrate; UK-14304-18-d4; AGN-190342-LF-d4; Alphagan-d4; Brimonidine-d4 D-Tartrate

Database IDs

• PubChem SID: 162256842
• PubChem CID: 71314199

CALCULATED PROPERTIES

• H Acceptors: 5
• H Donor: 2
• LogD (pH = 5.5): -0.8992662
• LogD (pH = 7.4): 0.41908175
• Log P: 1.3715845
• Molar Refractivity: 68.4944 cm^3
• Polarizability: 26.612413 Å^3
• Polar Surface Area: 62.2 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO
• Apperance: Off-White Solid
• Melting Point: 203-205°C (dec.)

Safety Information

• Storage Condition: -20°C Freezer

DETAILS

Toronto Research Chemicals - B677532

Labelled Brimonidine. It is an α2 receptor agonist. It is a drug used to treat glaucoma.

REFERENCES

• Katz, L.J., et al.: Am. J. Ophthalmol., 127, 20 (1999)
• Cantor, L. B., Expert Opin. Pharmacother., 1, 815 (1999)